Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be

  • 0 views
  • 24 Mar, 2022
  • 1 location
The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

study is to assess whether Camostat, a serine protease inhibitor available in an oral formulation has the potential to be studied as an antiviral drug in a large scale ambulatory setting to prevent

  • 0 views
  • 02 Sep, 2021
  • 1 location
An Open-Label Study of Apabetalone in Covid Infection

The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection

  • 4 views
  • 22 Mar, 2022
  • 1 location
The Late Presenter Treatment Optimisation Study (LAPTOP)

HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe

emtricitabine
hiv viral load
opportunistic infection
tenofovir
cobicistat
  • 124 views
  • 16 May, 2022
  • 43 locations
Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients (UTI-RTOM-NPC)

This is a phase 3, open-label, multicenter, randomized controlled phase III clinical trial. The purpose of this study is to evaluate the efficacy of ulinastatin, a kind of protease inhibitor, in

  • 19 views
  • 26 Feb, 2022
  • 1 location
HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

including NNRTI resistance. The other ARV medication (protease inhibitor, entry inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and NNRTI, will not be changed.

  • 0 views
  • 03 Feb, 2021
  • 2 locations
Anti-inflammatory Therapy to Improve Outcomes After TPIAT

time of transplant: (1) the Tumor Necrosis Factor (TNF)-alpha inhibitor etanercept and (2) the serine protease inhibitor alpha-1 antitrypsin. Both agents are commercially available for clinical trials

  • 142 views
  • 10 Mar, 2022
  • 1 location
HIV-1 Infected Patients Phase II Trial Dual Combination Doravirine/Raltegravir Open Label

transcriptase inhibitors (NRTIs) plus either a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase inhibitor (INSTI). NRTIs and PIs have been associated to

  • 1 views
  • 12 Feb, 2021
  • 1 location
Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY)

A substudy of TMC114FD2HTX4004 that will perform glucose tolerance testing, adipose testing and MRI scan at baseline, 12 and 24 weeks post switch of ART medications.

  • 0 views
  • 28 Jun, 2022
  • 1 location
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).

  • 0 views
  • 27 Apr, 2022
  • 3 locations